Alveolar rhabdomyosarcoma is an aggressive pediatric cancer exhibiting skeletal-muscle differentiation. New therapeutic targets are required to improve the dismal prognosis for invasive or metastatic alveolar rhabdomyosarcoma. Protein kinase C iota (PKCi) has been shown to have an important role in tumorigenesis of many cancers, but little is known about its role in rhabdomyosarcoma. Our gene-expression studies in human tumor samples revealed overexpression of PRKCI. We confirmed overexpression of PKCi at the mRNA and protein levels using our conditional mouse model that authentically recapitulates the progression of rhabdomyosarcoma in humans. Inhibition of Prkci by RNA interference resulted in a dramatic decrease in anchorage-independent colony formation. Interestingly, treatment of primary cell cultures using aurothiomalate (ATM), which is a gold-containing classical anti-rheumatic agent and a PKCi-specific inhibitor, resulted in decreased interaction between PKCi and Par6, decreased Rac1 activity and reduced cell viability at clinically relevant concentrations. Moreover, co-treatment with ATM and vincristine (VCR), a microtubule inhibitor currently used in rhabdomyosarcoma treatment regimens, resulted in a combination index of 0.470 --0.793 through cooperative accumulation of non-proliferative multinuclear cells in the G2/M phase, indicating that these two drugs synergize. For in vivo tumor growth inhibition studies, ATM demonstrated a trend toward enhanced VCR sensitivity. Overall, these results suggest that PKCi is functionally important in alveolar rhabdomyosarcoma anchorage-independent growth and tumor-cell proliferation and that combination therapy with ATM and microtubule inhibitors holds promise for the treatment of alveolar rhabdomyosarcoma.
INTRODUCTION
Rhabdomyosarcoma (RMS) is a group of aggressive muscle cancers and the most common soft tissue sarcomas in children and adolescents. 1 RMS can arise from skeletal muscle and nonmuscle tissues in the body and the prognosis is dependent on the site of origin and histological subtype.
2 Alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS) are the two major subtypes of RMS in children and adolescents and have distinct genetic abnormalities and biological behavior. 3 ARMS accounts for 25% of all RMS and is accompanied by a high frequency of invasion and metastasis at the time of initial diagnosis. Despite a multidisciplinary approach including surgical resection, irradiation and intensive chemotherapy, many children with invasive or metastatic ARMS die because of their disease. 4 Target discovery is ongoing to develop molecularly targeted therapies with the goal of improving prognosis. 5 Protein kinase C (PKC) is a family of serine/threonine kinases made up of at least 12 isozymes. 6 PKC isozymes have crucial roles in diverse cellular signaling processes including cellular proliferation, differentiation, apoptosis and angiogenesis. 7 PKC isozymes are classified into three major categories: classic (a, bI, bII and g), novel (d, e, Z and y) and atypical (x and i/l). Biochemical and immunological studies indicate that multiple PKC isozymes are expressed in virtually all cell and tissue types. 8 The expression of individual PKC isozymes is developmentally regulated and is responsive to the differentiation state of cells and tissues. The role of PKC isozymes in tumor biology is dependent on the cell type and intracellular localization and hence the different isozymes may have opposing effects in the same cell. 9 PKC isozymes have been implicated not only in the pathogenesis of many cancers including breast, colon, lung, prostate, pancreatic, liver and hematopoietic system, 8, 9 but also in the development of multidrug resistance. 9 --12 Although PKC isozyme expression varies in different cancers, only PKCi has been shown to be a human oncogene. 13, 14 PKCi has a pivotal role in the tumorigenesis of lung, pancreatic, prostate, colon and ovarian cancers. 15 --24 Recent findings suggested that this transformation can be prevented both in vitro and in vivo using a gold-containing classical anti-rheumatic agent, aurothiomalate (ATM). ATM disrupts the interaction between the PB1 domain of PKCi and Par6, 13, 18, 24, 25 a protein involved in the polarity-complex formation, 26 and inhibits Rac1 activity, which is a critical downstream effector of oncogenic PKCi. 27 Phosphorylation profiles in human ARMS and ERMS indicate that phosphorylation levels of PKCa, d, y and x are upregulated and hence could have roles in the development or progression of RMS. 28 Although few reports are available on the expression profile of the PKC family in RMS, involvement of individual PKC isozymes and their use as therapeutic targets are beginning to be explored. 8, 29, 30 Herein, we report the characterization of PKC isozymes in RMS, with a focus on the functional role of PKCi in the alveolar subtype of RMS. Moreover, our data hold forth the possibility that ATM might be an adjuvant therapy for use in combination with standard rhabdomyosarcoma chemotherapy.
RESULTS

PKCi is overexpressed in human rhabdomyosarcoma
Expression of PKC isoforms in RMS was determined using real-time reverse transcription (RT)-PCR in human skeletal muscle, ARMS and ERMS samples. A full profile is shown in Supplementary  Figure S1 . Among the isozymes, only PRKCI and PKCm were differentially increased in RMS tumors. Both ARMS and ERMS expressed PRKCI at 2 --4 orders of magnitude higher than normal skeletal muscle (Po0.05) (Figure 1a ). To determine if the overexpression of PRKCI was due to genomic amplification, the gene copy number of PRKCI in human ARMS DNA was compared with that in cases of lung squamous cell carcinoma harboring PRKCI amplification. No genomic amplification of PRKCI was observed in the examined cohort of PRKCI-overexpressing ARMS (Figure 1b) . To confirm that overexpression of PRKCI mRNA translated into overexpression of PKCi at the protein level, immunohistochemistry was performed on human ARMS and ERMS specimens (n ¼ 40 and n ¼ 5, respectively). ARMS tumors in particular demonstrated PKCi expression in 450% of cells for 77.5% of cases, whereas normal skeletal muscle rarely expressed strong PKCi (Figure 1c) . Thus, PKCi mRNA and protein are overexpressed in human ARMS and ERMS. PKCi was expressed in tumor cells but not in non-neoplastic cells in the tumor microenvironment.
PKCi is overexpressed in a rhabdomyosarcoma mouse model To validate that our mouse models of ARMS and ERMS reflect the characteristics of human RMS tumors, expression of Prkci in murine ARMS or ERMS was compared with normal mouse skeletal muscle using real-time RT--PCR ( Figure 2a ). As seen in human RMS, mouse ARMS and ERMS overexpressed Prkci to a level 7-to 35-fold higher than that in normal mouse skeletal muscle. Immunohistochemistry on paired mouse skeletal muscle and RMS tumor samples indicated consistently strong Prkci expression levels in tumors as compared with skeletal muscle (representative results are shown in Figure 2c ). We next focused on ARMS, given the particularly poor prognostic outcomes seen in the clinic. 4 To demonstrate that PKCi was not only expressed but also activated in ARMS, immunoblotting was performed to determine the expression and phosphorylation of PKCi on paired skeletal muscle and tumor samples. PKCi was overexpressed and highly activated in the primary tumors relative to normal skeletal muscle (Figure 2b ). ARMS primary cell cultures (U20325, U21459 and U23674) established from biopsies taken at necropsy from mice were used to analyze the PKCi signaling axis in ARMS, in vitro. Mouse primary cell cultures exhibited high expression of Prkci at the mRNA level compared with a normal mouse myoblast cell line C2C12 (Figure 2d ). The expression and activation of PKCi at the protein level was higher in the primary cell cultures when compared with C2C12, as confirmed by immunoblotting (Figure 2e and Supplementary Figure S2) , and reflected the trend observed at the mRNA level for primary cell cultures (Figure 2a ).
Suppression of PKCi inhibits mouse tumor cell colony formation in vitro
To confirm the role of PKCi in ARMS cells, a mouse-specific Prkci small interfering RNA (siRNA) was transfected into mouse primary cell cultures. Immunoblotting was used to confirm depletion of PKCi. Prkci siRNAs at X1 nM depleted total PKCi and its Figure S3 ). Anchorage-independent colony formation was also markedly inhibited at 10 --100 nM of Prkci siRNA (Figure 3b ). In contrast, primary cell cultures transfected with Prkci siRNA did not show a decrease in growth when treated with 1 --100 nM Prkci siRNA (Figure 3c ). These results are consistent with previous findings in intestinal epithelial cells, non-small-cell lung carcinoma cells, pancreatic cancer cells and ovarian cancer cells, which also showed inhibition of anchorage-independent colony formation but not growth. 18,19,22 --24 ATM inhibits mouse tumor cell proliferation in vitro In an effort to translate these studies to the clinic, ATM, a highly selective inhibitor of PKCi, was used to inhibit PKCi function in mouse ARMS primary cell cultures. ATM was identified through a high-throughput drug screen for its ability to inhibit PKCi binding to its effector, Par6, in vitro. 24 PKCi-mediated transformation requires activation of the more downstream effector molecule, Rac1. PKCi regulates Rac1 through interaction with Par6. 18 Our previous studies demonstrated that ATM is particularly effective as an anti-tumor agent in tumor cells that express elevated levels of Figure S2 for full-length blots of (e).
its target PKCi. 17 Given our current observation that ARMS tumors express high levels of PKCi, we hypothesized that ATM would have anti-tumor activity against ARMS. In our experiments, immunoprecipitation of PKCi and Par6 revealed that the PKCi --Par6 interaction in ARMS cells was decreased by ATM at clinically achievable concentrations in a dose-dependent manner ( Figure 4a and Supplementary Figure S4 ). To determine if PKCi was important for invasion of tumor cells, we performed an invasion assay with primary cell cultures treated with increasing concentrations of ATM (10--500 mM) (Figure 4b ). No statistical difference was found in the number of cells invading through the extracellular matrix chamber between untreated and treated cells except at high concentration of ATM (500 mM). Next, primary cell cultures were treated with increasing concentrations of ATM (10--1000 mM) (Figure 4a ). Interestingly, the growth of primary cell cultures was inhibited to a greater degree than for C2C12, which is a mouse myoblast cell line. For ARMS primary cell cultures the IC50 ranged from 54 to 166 mM.
Treatment with VCR and ATM has a synergic effect through G2 phase-mediated non-proliferative multinuclear cell accumulation We next investigated co-treatment with ATM and vincristine (VCR) because of the recently demonstrated role of Rac1 in mitosis. 31 --33 In a cell-growth assay, ATM increased the VCR sensitivity of mouse (Figure 6a ). Rac1 activation assay revealed that ATM treatment decreased Rac1 activity (Po0.05), whereas VCR treatment had no effect on Rac1 activity (Figure 6b ). To confirm these findings, we performed immunocytochemistry for b-tubulin and 4 0 ,6-diamidino-2-phenylindole (DAPI) with ATM-and/or VCRtreated cells. The number of multinuclear cells (MNC) was increased by VCR, and a statistically significant difference was found in the number of MNC between VCR alone and VCR plus ATM (Po0.05) (Figure 6c ). Moreover, Ki67 immunofluorescence showed that the population of non-proliferative MNC was increased by ATM and VCR (71.2% vs 58.8% Ki67-positive MNC with VCR þ ATM vs VCR alone) (Po0.05) (Figure 6c and Supplementary Figure S6 ). These MNC did not have activated apoptosis as measured by Cleaved Caspase-3 stain, TUNEL assay or Annexin-V/PI stains assay, cellular senescence as measured by senescence-associated b-galactosidase stain, or muscle differentiation as detected by myosin heavy chain expression (Supplementary Figure S7 ).
ATM enhanced VCR sensitivity in vivo Next, we assessed the effect of combination treatment with ATM and VCR in vivo. We previously showed that the serum gold level associated with a dose of ATM 60 mg/kg intramuscular injection daily for mouse was consistent with the serum gold level typically observed in rheumatoid arthritis patients undergoing ATM therapy. 17 VCR dose was chosen at 1 mg/kg based on previous reports. 36, 37 Tumor growth exhibited a consistently decreased trend in the ATM-treated group compared with the control group.
Whereas VCR was able to decrease tumor growth significantly, ATM led to a consistent trend to improve VCR sensitivity in vivo although this trend did not reach significance (Figure 7a and Supplementary Table S2a) . With regard to differential toxicity, no significant differences in mice body weight between control vs ATM-treated group, and VCR vs VCR þ ATM-treated group were observed (Figure 7b and Supplementary Table S2b) .
DISCUSSION
Rhabdomyosarcomas are the most common tissue sarcomas in children. Despite efforts to improve treatment regimens, the survival rate for RMS, especially ARMS, has remained unchanged for the past two decades; the 4-year survival rate for patients with Figure S4 for full-length blots of (a).
Protein kinase C iota in rhabdomyosarcoma K Kikuchi et al metastatic ARMS expressing PAX3-FKHR was reported to be 20% or less. 2, 3, 38 These poor clinical outcomes have fueled the need for a better understanding of the tumorigenic mechanisms so that new therapeutic targets/opportunities can be identified. 5 Recently, PKCi had been identified as an oncogene in non-small-cell lung cancer.
14 Overexpression of PKCi has been linked to progression and metastases of many cancers such as lung, prostate, pancreatic, colon, esophageal, liver, breast, ovarian and brain tumor. 8, 27 In this report, we conducted the first known study to determine the role of PKCi in ARMS tumorigenesis and explore its potential as a therapeutic target in this disease. To establish the relevance of PKCi in RMS tumorigenesis, we first confirmed that PKCi is overexpressed in human RMS vs normal skeletal muscle. While overexpression of PRKCI mRNA is attributable to tumorspecific gene amplification of PRKCI in squamous-cell carcinomas of the lung, 14 we found no genomic amplification of PRKCI in the RMS samples we tested, though examination of a larger cohort of human tumors may be warranted. We have also shown that PKCi protein overexpression parallels its mRNA overexpression in human tumors. We validated that our conditional mouse ARMS model had the same characteristics as human ARMS in terms of PKCi overexpression at the mRNA and protein levels and thus could be used to study the role of PKCi in ARMS tumorigenesis.
While our work is the first to examine the role of PKCi in ARMS, a role for other PKC isoforms in RMS is also emerging. Many of these studies have resulted from the ability of the broad-spectrum PKC-activating compound 12-O-tetradecanoyl-phorbol-13-acetate (TPA) to induce differentiation in ERMS and ARMS cell lines. 39 --41 More specific reports have demonstrated that PKCa, PKCd, PKCy and PKCz may be phosphorylated in approximately two-thirds of ARMS and half of ERMS. 28 One therapeutically based study has gone so far as to suggest that PKC isoforms may be required for phosphorylation and activation of the Pax3:Fkhr chimeric transcription factor in ARMS. 29 Another study indicated that PKCm and PKCe (and perhaps PKCy) are mediators of Igf-1 protection against rapamycin-induced apoptosis in a Pax3:Fkhr-expressing ARMS. 42 Meanwhile, other studies are focused on the roles of PKC isoforms upstream or downstream of cell surface-interacting proteins. For example, in an ERMS cell line, PKCe was suggested to have a role in cell-surface localization of microenvironment-interacting metalloproteases, 43 whereas PKCz was thought to have a role downstream in the response to IL-1beta. Recently we and others have shown that PKCi drives anchorage-independent growth of lung, colon and ovarian cancers. 14, 18, 22, 23 Using RNA interference, we have now established that PKCi also has a role in ARMS transformation as measured by anchorage-independent growth. Genetic inhibition of Prkci reduced the relative number of colonies formed by ARMS Protein kinase C iota in rhabdomyosarcoma K Kikuchi et al primary cell cultures but had no effect on a normal mouse myoblast cell line. We evaluated PKCi as a therapeutic target using the selective PKCi inhibitor ATM: a therapeutic agent we recently discovered and have taken into clinical trials for lung cancer (Clinicaltrials.gov, NCT 00575393). ATM reduced not only the interaction of PKCi --Par6 but also proliferation of mouse ARMS cells. ATM trough concentrations observed during ATM treatment of rheumatoid arthritis patients are 15.4 --25.4 mM, 34 which is slightly higher than the IC50 for our mouse ARMS cells. We next investigated the synergic effect of ATM and VCR, which binds to tubulin and inhibits microtubule formation, thereby arresting the cell at metaphase by disrupting the formation of the mitotic spindle. 45 Interestingly, ATM enhanced the VCR sensitivity of mouse ARMS cells and their combination index is below 1 at clinically achievable concentrations, indicating that ATM synergizes with VCR. For example, combination indices of 25 mM ATM and 5 nM VCR for U23674, U21459 and U20325 were 0.793, 0.572 and 0.470, respectively. Moreover, we obtained comparable results from in vivo experiments. Cell-cycle analysis indicated that the combination of ATM and VCR induced significantly more G2 and X4N cells compared with VCR alone. Immunofluorescence indicated that the combination of ATM and VCR induced significantly more Ki67-negative MNC compared with VCR alone. It has been previously shown that MNC arising after VCR are incapable of proliferation and do not contribute to tumor regrowth. 46 Moreover, Rac1 is a major downstream effector of PKCi --Par6 signaling axis that is inhibited by ATM 27 and is known as a regulator of mitosis. 31 --33 In our study, Rac1 activity was reduced by ATM but not by VCR. Based on these results, we hypothesize that treatment with VCR and ATM synergizes through G2 phase-mediated non-proliferative and MNC accumulation (Figure 6d) . We conclude that combination therapy with VCR and ATM should be investigated further for the clinical treatment ARMS and that, especially for children with VCR-associated peripheral neuropathy, adding ATM might be an approach to improve efficacy despite VCR dose reduction. Furthermore, the greatest therapeutic value of a well-tolerated agent such as ATM may be in combination with other targeted therapeutics, which is an avenue of ongoing investigation.
MATERIALS AND METHODS Mice
All animal procedures were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Texas Health Science Center at San Antonio (UTHSCSA) and the Oregon Health & Science University (OHSU). The Myf6Cre,Pax3:Fkhr,p53 conditional mouse model of ARMS has been described previously. 47 --49 The Pax7CreER,Ptch1,p53 conditional model of ERMS is described in Rubin et al.
50
Human tissue samples Human samples were obtained from the Pediatric Cooperative Human Tissue Network (Columbus, OH, USA) with approval from the UTHSCSA and OHSU institutional review boards.
Primary tumor-cell cultures and cell lines
Mouse primary cell cultures (U20325, U21459, and U23674) were established from tumor samples. Tumors were minced into small pieces and digested with collagenase (10 mg/ml) overnight at 37 1C. The dissociated cells were then incubated in Dulbecco's modified Eagle's media supplemented with 10% fetal bovine serum (FBS) and 1% penicillinstreptomycin in 5% CO 2 at 37 1C. C2C12 mouse myoblast and Rh30 human ARMS cell line were purchased from ATCC (Manassas, VA, USA) and maintained in the same culture conditions as primary tumor cell cultures.
Quantitative PCR analysis for PRKCI gene amplification Genomic DNA from each human tumor was analyzed for PRKCI gene amplification using Taqman technology on an Applied Biosystems 7900HT sequence-detection system. The human Rnase P1 gene was used as a DNA template control and for normalization of results. The primer/probe set for the human PRKCI gene was forward primer, 5 0 -GGCTGCATTCTTGCTTTCA GA-3 0 ; reverse primer, 5 0 -CCAAAATATGAAGCCCAGTAATCA-3 0 ; and probe, 5 0 -CAATCTTACCTGCTTTCT-3 0 . The primer/probe set for Rnase P1 gene was designed and provided by ABI Assay on Demand (Applied Biosystems, Foster City, CA, USA). A tumor was scored positive for PRKCI gene amplification when analysis revealed a minimum of one extra copy of the PRKCI allele.
Gene expression analysis
Total RNA was isolated from tumors using Trizol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. RNA was then purified using Qiagen RNeasy miniprep cleanup kit (Qiagen, Valencia, CA, USA). Single-stranded cDNA was generated from total RNA using first-strand synthesis kit (Fermentas, Hanover, MD, USA). Real-time PCR was performed using SYBR green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) on an ABI Prism 7500HT sequence-detection system. Primers used were as follows: human PRKCI (5 0 -TACGGCCAGGAGATACAACC-3 0 and 5 0 -TCGGAGCTCCCAACAATATC-3 0 ) and mouse Prkci (5 0 -GCAGATCCGCATCC CGCGTT-3 0 and 5 0 -AATGCTGTGGGGGCTGGTGC-3 0 ).
Histology and immunohistochemistry
Mouse tumor samples were fixed in 10% buffered formalin and embedded in paraffin. Paraffin sections (3.5 mm) were stained with hematoxylin and eosin (H&E). Immunohistochemistry was performed on paraffin sections by adhering to the manufacturer's protocol using rabbit anti-PKCi antibody (cat. ab5282, Abcam, Cambridge, MA, USA).
Immunoprecipitation and immunoblotting
Tumors were lysed in radioimmunoprecipitation assay buffer or NP40 buffer containing both protease and phosphatase inhibitor (Sigma Aldrich, St Louis, MI, USA). The lysates were homogenized and centrifuged at 8000 g for 10 min. 
Rac1 assay
Mouse RMS primary cell cultures were plated at 6 Â 10 4 cells per well in a six-well plate. After 24 h, ATM and VCR were added to the dish and, after 24 h, cells were harvested and Rac1 activity was analyzed by using Rac1 G-LISA Activation Assay (luminescence) (cat. BK126; Cytoskeleton, Denver, CO, USA).
Cell-cycle analysis
Mouse RMS primary cell cultures were plated at 3 Â 10 5 cells per 60-mm dish. After 24 h, ATM and VCR were added to the dish. After 24 h, cells were Protein kinase C iota in rhabdomyosarcoma K Kikuchi et al harvested, fixed with 70% cold ethanol, washed once in PBS, re-suspended in 50 mg/ml propidium iodide solution containing 200 mg/ml boiled RNase, incubated at room temperature for 30 min in the dark, and analyzed by flow cytometry using a Becton Dickinson FACScan. Cell cycle was determined with the WEASEL software (WEHI Biotechnology Centre, Bundoora, VIC, Australia).
In vitro growth-inhibition assays
Mouse RMS primary cell cultures were plated at 3 Â 10 3 cells per well in a 96-well plate. After 24 h, ATM and VCR were added to the wells in a range of concentrations by serial dilution. siRNA against mouse Prkci was purchased from Dharmacon (LQ-040822-07, Lafayette, CO, USA). Transient transfections were carried out using Lipofectamine 2000 (Invitrogen). Nontargeting siRNA (D-001810, Dharmacon) was used as control. After cells were incubated with ATM or siRNA for 72 h, cytotoxic effects were assayed using CellTiter 96 AQueous One Solution Cell Proliferation Assay system (Promega, Madison, WI, USA) and SpectraMax M5 luminometer (Molecular Devices, Sunnyvale, CA, USA). IC50 and combination index were determined with CalcuSyn software (BIOSOFT, Cambridge, UK).
Anchorage-independent colony-formation assay Mouse RMS primary cell cultures were plated at 3 Â 10 4 cells per well in a six-well plate. The cells were transfected with siRNA (0, 10, 100 nM) before plating the top layer. Eight days after the cells were transfected with siRNA, colonies were fixed with methanol, treated with Giemsa stain and counted.
Invasion assay
Invasion assay was performed using the Culturex 96 well BME invasion assay kit (cat. no. 3455-096-K, R&D systems, Minneapolis, MN, USA). Twenty-four hours before beginning the assay, cells were starved in a serum-free medium. Top chambers were plated at a density of 5 Â 10 4 cells per well in 50 ml with DMEM and ATM at different concentrations (0 --500 mM). The bottom chambers were filled with 10% of fetal bovine serum/DMEM or DMEM only as a negative control. The relative invasion was determined after 24 h of incubation using calcein --AM solution by reading the plate at 485 nm excitation and 520 nm emission wavelengths.
In vivo orthotopic allograft tumor-growth inhibition studies All experiments received prior approval from the OHSU Institutional Animal Use and Care Committee. SHO-Prkdc scid Hr hr mice aged 4 --8 weeks (Charles River Laboratories International, Inc., Wilmington, MA, USA) were injected with 1 Â 10 6 cells from mouse primary cell cultures into the cardiotoxin-preinjured gastrocnemius muscles. Three days after injection, drug treatment started. Seven mice or five mice were used in control or each treatment group. Tumor volumes (cm 3 ) were measured threedimensionally with an electronic calipers and were calculated using the formula (p/6) Â length Â width Â height, assuming tumors to be spheroid.
Statistical analysis
All data are presented as mean ± s.d. One-way ANOVA was used to determine the statistical significance of expression analysis and in vitro assay. Po0.05 was considered to be statistically significant.
Statistical analysis of in vivo orthotopic allograft tumor-growth inhibition studies Treatment groups were contrasted by pairwise comparisons between treatment groups with regard to mean tumor size using a repeatedmeasures linear model with an auto-regressive covariance structure adjusted for aday, treatment group and the interaction of day treatment, and corrected for multiple testing using the Tukey method. Mean body weight by treatment groups were also compared using a repeatedmeasures linear model with an auto-regressive covariance structure adjusted for day and treatment group and corrected for multiple testing using the Tukey method. The interaction of day treatment was not significant in the model.
